Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.

Scientific reports - 16 Mar 2026

Leich-Zbat Ellen, Heredia-Guerrero Sofia Catalina, Evers Marietheres, Stühmer Thorsten, Grieb Tina, Rauert-Wunderlich Hilka, Bargou Ralf C, Rosenwald Andreas, Chatterjee Manik, Brünnert Daniela

Abstract excerpt

The introduction of proteasome inhibitors (PIs) into multiple myeloma (MM) treatment has substantially improved therapeutic options and survival rates. However, the development of resistance to PIs as well as serious side effects of PI treatment continue to justify the search for effective, less burdensome combination therapies. Thus, we investigated the therapeutic potential of VS-4718 (dual pPYK2- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Synergism

Share to Multiple Myeloma

Share to Oligopeptides

Share to Proteasome Endopeptidase Complex

Share to Proteasome Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41839959
DOI: 10.1038/s41598-026-43205-4
PMCID: PMC12996346

Genes

PSMB5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.PMID 41839959Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaSemantic proximity Read ↗

Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive ReviewSemantic proximity Read ↗

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradationSemantic proximity Read ↗

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor PicropodophyllinSemantic proximity Read ↗

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Clinically relevant pulse-treatment generates bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclaxSemantic proximity Read ↗

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphomaSemantic proximity Read ↗

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaSemantic proximity Read ↗

<scp>PI</scp>3K‐dependent multiple myeloma cell survival is mediated by the <scp>PIK</scp>3<scp>CA</scp> isoformSemantic proximity Read ↗

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.